India Vanishing Bone Disease Market

ID: MRFR/HC/54340-HCR 200 Pages Nidhi Mandole Last Updated: September 17, 2026
India Vanishing Bone Disease Market Research Report By Diagnosis (X-rays, CT Scans, MRIs, Ultrasound, Nuclear Medicine, Others), By Treatment (Medicine Therapy, Radiation Therapy), and By End User (Hospitals, Diagnostic Centers, Others) - Growth & Industry Forecast 2025 To 2035
India Vanishing Bone Disease Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)10.5%
2024 Market Size$ 200 Million
2025 Market Size$ 221 Million
2035 Market Size$ 600 Million
Key Players
Amgen
Novartis
Bristol-Myers Squibb
Eli Lilly and Company
Roche
Pfizer
Trends
  • Increased Research Funding
  • Emergence of Advanced Therapeutics
  • Growing Patient Advocacy
Opportunities
  • Emergence of Targeted Therapies
  • Increased Awareness and Education
  • Government Initiatives and Support
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Chemicals and Materials, BY Diagnosis (USD Million)
      1. 4.1.1 X-rays
      2. 4.1.2 CT scans
      3. 4.1.3 MRIs
      4. 4.1.4 ultrasound
      5. 4.1.5 nuclear medicine
      6. 4.1.6 others
    2. 4.2 Chemicals and Materials, BY Treatment (USD Million)
      1. 4.2.1 Medical Therapy
      2. 4.2.2 Radiation Therapy
    3. 4.3 Chemicals and Materials, BY End-User (USD Million)
      1. 4.3.1 Hospitals & Clinics
      2. 4.3.2 Diagnostic Centers
      3. 4.3.3 Ambulatory Surgical Centers
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Amgen (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Bristol-Myers Squibb (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Eli Lilly and Company (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Roche (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Pfizer (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sanofi (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Merck & Co. (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 INDIA MARKET ANALYSIS BY DIAGNOSIS
    3. 6.3 INDIA MARKET ANALYSIS BY TREATMENT
    4. 6.4 INDIA MARKET ANALYSIS BY END-USER
    5. 6.5 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF CHEMICALS AND MATERIALS
    8. 6.8 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    10. 6.10 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
    11. 6.11 CHEMICALS AND MATERIALS, BY DIAGNOSIS, 2024 (% SHARE)
    12. 6.12 CHEMICALS AND MATERIALS, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
    13. 6.13 CHEMICALS AND MATERIALS, BY TREATMENT, 2024 (% SHARE)
    14. 6.14 CHEMICALS AND MATERIALS, BY TREATMENT, 2024 TO 2035 (USD Million)
    15. 6.15 CHEMICALS AND MATERIALS, BY END-USER, 2024 (% SHARE)
    16. 6.16 CHEMICALS AND MATERIALS, BY END-USER, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DIAGNOSIS, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
      3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

India Vanishing Bone Disease Market Segmentation

India Vanishing Bone Disease Market By Diagnosis (USD Million, 2025-2035)

  • X-rays
  • CT scans
  • MRIs
  • ultrasound
  • nuclear medicine
  • others

India Vanishing Bone Disease Market By Treatment (USD Million, 2025-2035)

  • Medical Therapy
  • Radiation Therapy

India Vanishing Bone Disease Market By End-User (USD Million, 2025-2035)

  • Hospitals & Clinics
  • Diagnostic Centers
  • Ambulatory Surgical Centers

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.